JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Odonate Therapeutics Inc

Fermé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Odonate Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 23:08 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 23:07 UTC

Résultats

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:20 UTC

Résultats

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 avr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 avr. 2026, 23:22 UTC

Résultats

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 avr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 avr. 2026, 22:52 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:33 UTC

Résultats

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 avr. 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 avr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 avr. 2026, 22:05 UTC

Résultats

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 21:57 UTC

Résultats

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 avr. 2026, 21:55 UTC

Résultats

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 avr. 2026, 21:53 UTC

Résultats

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparaison

Variation de prix

Odonate Therapeutics Inc prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat